SCOTTSDALE, Ariz., Oct. 4 /PRNewswire-FirstCall/ -- MedCom USA, Inc. (OTC:EMED) (BULLETIN BOARD: EMED) today announced that an independent valuation of the market value of the patent (U.S. Patent 6,032,859) owned by Card Activation Technologies Inc. (Pink Sheets: CDVT) for a method of processing debit purchases is $3,732,096,059. MedCom owns approximately 40% of the issued shares of Card Activation Technologies Inc. Card Activation Technologies also said that the company's Form 211 application has been filed with the NASD for a listing of the shares to be traded on the OTC Bulletin Board. The company stated that the trading that is currently taking place is not on the OTC Bulletin Board on which the company applied but on the pink sheets, under the symbol, CDVT.PK, which commenced on Thursday, September 27. The company expects that the OTC Bulletin Board trading should commence shortly. The independent valuation of the Card Activations patent by Chapin Associates Ltd. of Northfield, Illinois, provides an estimated market value of the asset of Card Activation. The method used for determining the value was a discounted future benefit stream based on market comparable licenses (royalty rates). The royalty rate that Chapin Associates used in arriving at it's over $3.7 billion valuation was based on a conservative figure, and Card Activation may assert higher royalty rates against companies that infringe its patent. In its summary, Chapin Associates cited HSN Consultants, Inc. (1999-2005) as indicating that the "value of prepaid card purchases increased from $30.31 billion in 1999 to $115.79 billion in 2004," growth that exceeded prior projections. Furthermore, according to a study by the Federal Reserve Bank of Philadelphia in Mach 2007 prepaid cards accounted for $181.7 Billion in transactions in 2006. According to the report, to reach the valuation of $3.7 billion, Chapin determined the potential revenue that could be generated from the patent, as well as the approximate growth rate to apply to this revenue stream for the next seven years (Actual length of time remaining on the patent is 10 years). It then discounted the royalty income for the seven-year period to net present value to arrive at a value for each market segment. Because technology can quickly become obsolete, Chapin also included a 6.3% premium to the discount rate to account for functional obsolescence. Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of MedCom USA Inc (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) fulfill its business plan; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at http://www.sec.gov/ under "Search for Company Filings." DATASOURCE: MedCom USA, Inc. CONTACT: Kent Barghols, +1-515-276-1180, for MedCom, USA Inc. Web site: http://www.medcomusa.com/

Copyright